Karl I. Lanocha, MD – Course Chair

Dr. Lanocha has more than 25 years of experience in neuromodulation therapies for treatment-resistant depression, including both TMS and ECT. He was among the first physicians in the country to begin offering TMS when it was approved by the FDA in 2008. He has lectured widely about TMS. His research activities have focused on long-term clinical outcomes following TMS treatment for major depression.

Richard A. Bermudes, MD

Dr. Bermudes is Medical Director at TMS Health Solutions. He is the former president and a current board member of the Clinical TMS Society, a professional association dedicated to optimizing clinical practice, awareness, and affordability of Transcranial Magnetic Stimulation therapy. He has consulted with TMS industry leaders to help formulate insurance coverage policies for TMS therapy.

Ian A. Cook, MD

Dr. Cook is Director of the UCLA Depression Research and Clinic Program at the Semel Institute and Founding Chief of the TMS Treatment Service in the UCLA Department of Psychiatry. His research focuses on improving existing treatments for depression and developing new treatments for depression and related disorders. As both a biomedical engineer and a physician, he is at the forefront of the rapidly expanding field of neuromodulation and has published landmark studies of several novel neuromodulation therapies.

Paul E. Croarkin, DO

Paul E. Croarkin, DO, is focused on understanding the neurobiology, optimal treatment and classification of mood disorders in children and adolescents. This includes studies of repetitive transcranial magnetic stimulation (rTMS) for adolescent major depressive disorder; collaborative clinical trials; studies of neurophysiology with magnetic resonance spectroscopy (MRS); and novel, single and paired-pulse transcranial magnetic stimulation (TMS) paradigms.

A central theme among Dr. Croarkin's research is investigating the role of gamma-aminobutyric acid (GABA) and glutamate neurotransmitter systems in early-onset mood disorders with the goal of informing safer and more effective biologic treatments. He is on the faculty at the Mayo Clinic in Minnesota.

Mark A. Demitrack, MD

Dr. Demitrack has extensive experience in the treatment of mood disorders. His research has focused on using TMS for treatment-resistant depression. He has written extensively on the neuroendocrinology of mood disorders.

Jonathan Downar, MD

Dr Jonathan Downar serves as the Co-Director of the MRI-Guided rTMS Clinic at University Health Network, and also holds the position of Scientist at the Toronto Western Research Institute. He completed a BSc in biology at McGill University, followed by a PhD in neuroimaging at the University of Toronto with Dr. Karen Davis, before obtaining his medical degree from the University of Calgary in 2005. He then returned to Toronto for his psychiatry residency training, during which he also completed a research fellowship in neuroeconomics with Dr. Read Montague at Baylor College of Medicine.

Dr. Downar joined the Department of Psychiatry at UHN on completion of his residency in 2010. Shortly thereafter, he established the MRI-Guided rTMS Clinic. As of October, 2015, the clinic has received over 1600 community referrals and delivered over 20,000 sessions of stimulation.

Mark S. George, MD

Dr. George is one of the world’s leading authorities on TMS. From his pioneering work at NIH, to the publication of one of the very first studies of TMS in the treatment of depression, to the pivotal trial leading to FDA approval of TMS and the subsequent NIMH replication trial, he is rightfully regarded as one of the “fathers “ of TMS. As editor of the Journal of Brain Stimulation, he helped forge a whole new specialty of neuropsychiatric medicine. In his capacity as Director of the Brain Stimulation Laboratory at the Medical University of South Carolina, his ongoing research is now focusing on TMS in the treatment of stroke and other neurological disorders.

Paul E. Holtzheimer, MD, MS

Dr. Holtzheimer is the Director of the Mood Disorders Service at Dartmouth Hitchcock Medical Center, where his research is focused on the neurobiology and treatment of mood disorders, primarily treatment-resistant depression. He has been an investigator in several clinical trials of novel treatments, including TMS and deep brain stimulation, as well as numerous studies investigating the structural and functional neuroanatomy of mood disorders.

Philip G. Janicak, MD

Previously at Rush University and now the Director of TMS at Linden Oaks, Dr. Janicak has long been regarded as a leading expert in psychopharmacology and neuromodulation, including both TMS and ECT. He has written extensively on the long-term safety and efficacy of TMS in treatment resistant-depression, including the pivotal study leading to FDA approval of TMS.

Shawn M. McClintock, PhD, MSCS

Dr. McClintock is Associate Professor in the Department of Psychiatry at UT Southwestern Medical Center, and is Adjunct Associate Professor in the Department of Psychiatry and Behavioral Sciences at Duke University School of Medicine. His clinical research has focused on neuropsychological evaluation and clinical outcomes assessment of patients undergoing TMS and other neuromodulation treatments for major depression and other neuropsychiatric disorders.

Nolan Williams, MD

Dr. Williams is an Instructor of Psychiatry at Stanford University, where his research program is focused on the development of new therapeutic approaches for treatment-resistant depression. He has been an investigator in several clinical trials of novel treatments, including intravenous ketamine and epidural cortical stimulation. Dr. Williams has been recently funded to complete several studies investigating the functional neuroanatomy of mood disorders with advanced imaging techniques. He is currently developing new forms of rTMS treatments such as accelerated theta-burst stimulation as well as biomarkers to measure the changes induced by rTMS such as resting-state functional connectivity MRI.

Ready to get started?

Receive continuing education credits for the course.

CALENDAR